Sanofi-Aventis (SNY +0.1%) increases its 2007 biotech deal with Regeneron Pharmaceuticals (REGN...

|About: Regeneron Pharmaceutica... (REGN)|By:, SA News Editor

Sanofi-Aventis (SNY +0.1%) increases its 2007 biotech deal with Regeneron Pharmaceuticals (REGN +15.1%), boosting its payment for R&D to $160M/year from $100M, and extending the pact by five years, through 2017. REGN chief Dr. Leonard S. Schleifer says the deal is a model of how Big Pharma can collaborate with biotech without suffocating it: "They leave Regeneron and its culture to do its thing." (PR)